A Single-center, Randomized, Open-labeled, Crossover Phase 1 Study to Evaluate the Pharmakinetics Effect of High Fat Food to Single Dose Administration of Anaprazole in Healthy Chinese Subjects
Overview
- Phase
- Phase 1
- Intervention
- Anaprazole
- Conditions
- Healthy Male Volunteers
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
- Enrollment
- 14
- Primary Endpoint
- Cmax of anaprazole (parent drug, KBP-3571) and its enantiomer（KBP-3570）and its major metabolites
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
A single-center, randomized, open-labeled, 2×2 crossover phase 1 study to evaluate the pharmakinetics effect of high fat food to single dose administration of Anaprazole in healthy Chinese male subjects. 14 health male subjects is divided to A group (n=7) and B group (n=7). 2 periods (7 days) cross-over design, anaprazole 40mg single dose, one is fasting oral administration before breakfast, the other is oral administration 30 minutes after breakfast with high fat food.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The subject is capable of understanding and complying with protocol requirements, and signed and dated a written informed consent form voluntarily;
- •The subject is a Chinese health male adult, aged 18 to 45 years, inclusive;
- •The subject weighed at least 50.0 kg and had a body mass index (BMI) between 19.0 kg/m\^2 and 24.0 kg/m\^2, inclusive;
- •Has clinical laboratory evaluations, vital signs and ECG testing within the reference range, and medical history and physicial examination results are normal. Participants with evaluations outside the reference range that are deemed not clinically significant by the investigator may be included at investigator discretion;
- •No medical history of allergy to proton pump inhibitors and no any other drug allergy history;
- •The subjects have a good lifestyle and can keep good communication with the investigators and comply with the requirements of clinical trial.
Exclusion Criteria
- •Has postural hypotension, gastrointestinal disease (gastric ulcer, gastritis and etc), liver disease, renal disease (nephritis, pyelonephritis and etc), and other disease or medical history of any other system (cardiovascular, respiratory, psychoneural, hematology, endocrinology and etc) ;
- •Has clinical significant abnormal electrolytes (especially hypopotassemia) in screening examination;
- •Has clinical significant ECG abnormal history or family history of long QT syndrome(Grandparents, parents and siblings);
- •Has rhinitis, allergic rhinitis, recurrent hemorrhinia, nasal deformity and abnormal nasal septum；
- •With positive result of drug screening test;
- •With positive result of nicotine test;
- •Female participants who are pregnant, breast-feeding or menstral period, or participants has no effective contraception method, or has pregnancy plan in 6 months;
- •Has received any drugs: acid-inhibitors, any priscription drug, herb medicine, non-prescription drugs and/or food suppliments (including vitamine) within 2 weeks before randomization;
- •Blood donation / blood loss ≥400 mL within 3 months, or participated any other clinical trials within 3 months;
- •Known Human immunodeficiency virus antibody, hepatitis B surface antigen, hepatitis C antibody, and Treponema pallidum specific antibody test results were positive at screening;
Arms & Interventions
High fat food oral administration
Anaprazole 40mg, single dose, oral administration 30 minutes after breakfast with high fat food.
Intervention: Anaprazole
Fasting oral administration
Anaprazole 40mg, single dose, oral administration before breakfast.
Intervention: Anaprazole
Outcomes
Primary Outcomes
Cmax of anaprazole (parent drug, KBP-3571) and its enantiomer（KBP-3570）and its major metabolites
Time Frame: 10 minutes pre-dose and 1.5、2、2.5、3、3.5、4、4.5、5、6、7、8、10、12、15、24 hours post-dose
Cmax is the peak plasma concentration
AUC of anaprazole (parent drug, KBP-3571) and its enantiomer（KBP-3570）and its major metabolites
Time Frame: 10 minutes pre-dose and 1.5、2、2.5、3、3.5、4、4.5、5、6、7、8、10、12、15、24 hours post-dose
AUC is area under the plasma concentration-time curve
Tmax of anaprazole (parent drug, KBP-3571) and its enantiomer（KBP-3570）and its major metabolites
Time Frame: 10 minutes pre-dose and 1.5、2、2.5、3、3.5、4、4.5、5、6、7、8、10、12、15、24 hours post-dose
Tmax is the time to peak plasma concentration